19 June 2013
Keywords: fomivirsen, delays, cmv, retinitis, progression, isis, pharmaceuticals
Article | 08 April 1998
Isis Pharmaceuticals and Ciba Vision, a unit of Novartis, have revealeddata from Phase III trials which demonstrate that the antisense ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 April 1998
7 April 1998
6 April 1998
© 2013 thepharmaletter.com